Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch later this year in the United States and in 2011 in Europe and Japan, Forest Laboratories/AstraZeneca/Takeda's ceftaroline will earn peak year sales of up to $200 million in the community-acquired pneumonia drug market.

The Pharmacor 2010 findings from the topic entitled Community-Acquired Pneumonia reveal that sales of the broad-spectrum cephalosporin ceftaroline will be driven by its activity against methicillin-resistant Staphylococcus aureus (MRSA), physician familiarity with cephalosporins and the lack of competition it will face from Basilea's ceftobiprole through 2015.

"Ceftaroline is poised to be the only anti-MRSA cephalosporin on the market for community-acquired pneumonia between 2010 and 2015," said Decision Resources Therapeutic Area Director Danielle Drayton, Ph.D. "Surveyed clinicians are very excited about the development of novel cephalosporins and, as physician awareness of ceftaroline increases, we expect its uptake to steadily increase through 2018."

Because there are few drugs in late-stage development for the indication, ceftaroline has the potential to be an important therapeutic option for patients hospitalized with community-acquired pneumonia. In the hospital setting, ceftaroline will compete with the most recently approved drug for community-acquired bacterial pneumonia, Pfizer's Tygacil, as well as Johnson & Johnson's blockbuster agent, Levaquin.

The Pharmacor 2010 findings also reveal that, from 2008 to 2018, the patent expiries of three blockbuster antibiotics--levofloxacin, moxifloxacin and piperacillin/tazobactam--will be the primary factors contributing to a decrease of more than 15 percent in the community-acquired pneumonia drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The generic erosion of levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit), moxifloxacin (Bayer/Merck/Shionogi's Avelox) and piperacillin/tazobactam (Pfizer's Zosyn and Taisho Toyama's Tazocin) will decrease the overall market by more than $130 million from 2008 to 2018.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, Inc.,
+1-781-296-2597, ccomfort@dresources.com

New Study By BioTrends Highlights Changes in the Management of Gout and Hyperuricemia Among Rheumatologists and Primary Care Physicians

View Now